Condition
Humoral Rejection
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Unknown1
Not Yet Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05890430Not Yet Recruiting
Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation
NCT03801135Not ApplicableUnknownPrimary
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
NCT01895127Phase 2Terminated
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Showing all 3 trials